- Home
- RSSS vs ANVS Comparison
RSSS vs ANVS Comparison
Compare RSSS & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RSSS | ANVS |
|---|---|---|
| Founded | 2006 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.9M | 76.6M |
| IPO Year | 2008 | 2019 |
Fundamental Metrics
Financial Performance| Metric | RSSS | ANVS |
|---|---|---|
| Price | $1.98 | $1.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $5.00 | ★ $13.50 |
| AVG Volume (30 Days) | 33.3K | ★ 1.1M |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 125.00 | 39.39 |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $28,793,922.00 | N/A |
| Revenue This Year | $1.81 | N/A |
| Revenue Next Year | $5.73 | N/A |
| P/E Ratio | $21.89 | ★ N/A |
| Revenue Growth | ★ 2.77 | N/A |
| 52 Week Low | $2.00 | $1.10 |
| 52 Week High | $4.12 | $5.50 |
Technical Indicators
Market Signals| Indicator | RSSS | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 30.64 | 21.89 |
| Support Level | N/A | N/A |
| Resistance Level | $2.36 | $2.02 |
| Average True Range (ATR) | 0.09 | 0.10 |
| MACD | -0.02 | -0.06 |
| Stochastic Oscillator | 5.88 | 3.29 |
Price Performance
Historical ComparisonAbout RSSS Research Solutions Inc
Research Solutions Inc is a holding company. The company provides vertical software-as-a-service ("SaaS") and artificial intelligence ("AI") solutions, providing software and related services to help research-intensive organizations simplify the research process, save time, and money. The company operates in a single segment, which derives its revenue from subscription fees from its cloud-based SaaS Platforms and transactional service fees for the electronic delivery of single articles. The company generates the majority of its revenue from the Transactions. Geographically, the company generates the majority of its revenue from the United States, followed by Europe.
About ANVS Annovis Bio Inc.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.